screen and (2) cfDNA screening. We performed a literature review to model rates of insufficient fetal fraction, invasive testing for abnormal results, test performance characteristics, incidence of T21, rates of live birth, termination, and stillbirth in each clinical scenario. Costs of screening, invasive testing, termination, procedurerelated fetal loss and of a T21 live birth were obtained from literature review. Primary outcomes of the model were the cost of each strategy, number of unnecessary invasive tests, procedure-related fetal losses, and missed cases of T21. RESULTS: In the base case, the mean cost of cfDNA was $453 greater than that of INT ($1,310 vs $857). cfDNA resulted in a lower probability of an unnecessary invasive test (2.9% vs 3.7%), procedurerelated fetal loss (0.015% vs 0.019%), and missed cases of T21 (0.00013% vs 0.02%), respectively. cfDNA cost $56,000 per unnecessary invasive test avoided, $11 million per procedure-related fetal loss avoided, and $2 million per missed case of T21 avoided. In sensitivity analysis, when the probability of an insufficient fetal fraction is assumed to be > 25%, cfDNA is both costlier than INT and results in more unnecessary invasive testing (a dominant strategy). CONCLUSION: When compared to serum integrated screening, cfDNA is costlier and results in higher rates of unnecessary invasive testing in morbidly obese women with a probability of insufficient fetal fraction > 25%, which occurs at a maternal weight of approximately 300 pounds.
OBJECTIVE: Previous studies have suggested a relationship between a low fetal fraction of cell-free DNA (cfDNA) and gestational diabetes (GDM). The aim of this study was to determine the association between cfDNA fetal fraction and GDM in a cohort of patients presenting for cfDNA screening for fetal aneuploidy. STUDY DESIGN: Retrospective cohort study of women with singleton pregnancies who had cfDNA screening at a single institution at 10-20 weeks gestation between October 2011 and October 2017. GDM was defined using the Carpenter-Coustan criteria. Cases with fetal aneuploidy, stillbirth and unavailable outcome were excluded. Fetal fractions were adjusted for gestational age using multiples of the median. Multivariable logistic regression was used to estimate the odds ratio (OR) of GDM controlling for potential confounders. RESULTS: Among 2,623 pregnancies meeting inclusion criteria, 150 (5.7%) were diagnosed with GDM. Demographic characteristics were similar between the two groups ( Table 1 ). The mean gestational age and maternal age at the time of cfDNA screening were 12.8 weeks and 39.1 years, respectively. GDM was associated with increased BMI and older maternal age. Women with GDM had a lower fetal fraction (0.93 MoM v. 1.05 MoM, p ¼ 0.002). However, the association between fetal fraction and GDM was not significant after adjusting for BMI (OR 0.84, 95% CI 0.52-1.36; p¼0.475) ( Table 2 ). Since insulin resistance increases at later gestational ages, a separate analysis on women with gestational age 14-20 weeks at the time cfDNA screening was performed. Again, the association between fetal fraction and GDM was not significant after adjusting for BMI (OR 0.81, p¼0.672) . CONCLUSION: In this large retrospective cohort study, low cfDNA fetal fraction at 10-20 weeks gestation was not associated with the development of GDM. Although fetal fraction was lower among women diagnosed with GDM, this relationship was no longer statistically significant once maternal BMI was taken into account.
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